Valuation: Healios K.K.

Market Cap 34.97B 221M 189M 177M 162M 305M 21.09B 310M 2.09B 816M 10.58B 828M 810M P/E 2026 *
-8.05x
P/E 2027 * -12.4x
Enterprise Value 34.71B 219M 188M 175M 161M 303M 20.93B 308M 2.07B 810M 10.5B 822M 804M EV / Sales 2026 *
47.5x
EV / Sales 2027 * 3.99x
Free-Float
77.9%
Yield 2026 *
-
Yield 2027 * -
07-27 Healios Announces Selection of Akt-01/Hlcn061 Commercial Manufacturing Process for Amed Project CI
04-08 Japan Stocks Rise as US-Iran Ceasefire Eases Geopolitical Concerns MT
04-07 Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material MT
04-07 Healios to Supply Stem Cell Culture Material to JENECELL in Cosmetics Deal MT
04-07 Healios K.K. Enters Agreement with Jenecell to Supply Culture Supernatant CI
03-27 Healios K.K. Receives Grant Approval from Ministry of Economy, Trade and Industry for Subsidy Program to Support Capital Investment in Regenerative, Cell, and Gene Therapy Manufacturing Facilities CI
02-20 Healios Plans Capital Reduction to Eliminate Retained Losses MT
02-13 Healios K.K. announced that it has received ¥6.298588125 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
02-03 Healios K.K. Announces Start of ARDS Clinical Trial in Japan for the Global Phase 3 REVIVE-ARDS Study CI
01-29 Healios K.K. announced that it expects to receive ¥6.298588125 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
01-21 Healios Signs LOI with Alfresa for Ongoing Supply of Stem Cell Culture Supernatant MT
01-20 Healios K.K. Announces Submission of Clinical Trial Notification in Japan for the Global Phase 3 REVIVE-ARDS Study CI
01-20 Healios Submits Japan Trial Plan for Global Phase 3 ARDS Study MT
1 day-4.07%
1 week+0.39%
Current month+9.75%
1 month+1.17%
3 months-22.22%
6 months-30.38%
Current year-5.47%
1 week 255
Extreme 255
296
1 month 208
Extreme 208
296
Current year 208
Extreme 208
483
1 year 208
Extreme 208
628
3 years 114
Extreme 114
747
5 years 114
Extreme 114
2,557
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 01/03/2018
Director of Finance/CFO 49 16/07/2019
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 49 01/02/2012
Director/Board Member 49 01/03/2018
Director/Board Member 73 01/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-4.07%+0.39%-57.26%+17.19% 228M
-1.90%+2.37%+69.11%+110.88% 73.45B
+0.87%+17.17%+53.05%+95.59% 62.99B
+1.71%-1.44%+2.66%+501.29% 28.05B
-1.40%+4.18%+54.52%+19.60% 25.42B
+21.96%+21.90%+0.51%+2.50% 23.3B
+2.28%+7.98%+42.75%-12.34% 19.45B
0.00%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+17.17%+534.55% 16.53B
+2.39%+5.96%+44.04%+157.77% 13.16B
Average +1.93%+3.98%+47.05%+185.09% 28.08B
Weighted average by Cap. +1.70%+5.23%+57.00%+167.98%

Financials

2026 *2027 *
Net sales 730M 4.61M 3.95M 3.69M 3.39M 6.37M 441M 6.47M 43.56M 17.06M 221M 17.31M 16.93M 9.12B 57.53M 49.35M 46.08M 42.28M 79.51M 5.5B 80.82M 544M 213M 2.76B 216M 211M
Net income -4.03B -25.42M -21.81M -20.36M -18.68M -35.13M -2.43B -35.71M -240M -94.08M -1.22B -95.45M -93.37M -3.01B -18.98M -16.28M -15.2M -13.95M -26.22M -1.81B -26.66M -179M -70.23M -910M -71.25M -69.7M
Net Debt -260M -1.64M -1.41M -1.31M -1.2M -2.27M -157M -2.3M -15.49M -6.07M -78.58M -6.15M -6.02M 1.46B 9.23M 7.92M 7.39M 6.78M 12.76M 882M 12.97M 87.24M 34.16M 442M 34.66M 33.9M
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
19/08/26 ¥259.00 -4.07% 1,433,700
18/08/26 ¥270.00 +1.12% 1,660,400
17/08/26 ¥267.00 -1.84% 2,543,000
14/08/26 ¥272.00 -2.51% 3,530,700
13/08/26 ¥279.00 +9.84% 4,350,500
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
259.00JPY
Average target price
794.83JPY
Spread / Average Target
+206.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4593 Stock